Jean-Pierre Armand MD, MSc

Institut Gustave Roussy, Cancer Campus Grand Paris, France

Dr JP Armand focuses his cancer research in the field of new mechanism of oncogenese and early drug development.

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Di-rector of the Institut Claudius Regaud in Toulouse  . Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer)and opened in 2014.

After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Develop-ment at IGR.

Although expert in breast, head&neck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2 of new anticancer agents . He is  the founder of the IGR Phase I Unit (Ditep) in the early 80s.  He did the first in human phase I in the world at IGR of numerous drugs, now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxaliplatin, Tax-otere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus...

At present ,he and his colleagues are concentrating in Gustave Roussy DITEP  on new therapies for orphan treatment cancer diseas-es, with a special personal  investment in  cancer biotechs .

Dr Armand is active in the International Cancer community. He served as President of the European Society for Medical Oncology (ESMO), President of the French Cancer Society (SFC) Medical Director of the Federation of European Cancer Societies (FECS/ECCO) , Chairman of the Protocol Review Committee of  European Organization of Research , Treatment of Cancer (EORTC), Chairman of Oncology at French EMA (AFSSAPS), Member of International Boards of the American Association for Cancer Research (AACR), Member of scientific committee of the American Society of Clinical Oncology (ASCO) and AACR, Member of the board of clin-ical trials at Institut National du Cancer (INCa) and chairman of the president nominating committee of ESMO. He is member of the Chinese Society of Medical Oncology(CSCO) and did participate actively the creation of the first ESMO-Asia congress in Singapore in December 2016 . Dr. Jean-Pierre ARMAND is also proud to have been a mentor and teacher of multiple students, medical oncology fellows from all over the cancer world.

He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research.,CISCO journal.

After a 5 years as CEO of Institute Claudius Regaud in Toulouse, he is now (2015) back in Paris as senior consultant in the drug de-velopment department (DITEP)for Biotechs at Institute GUSTAVE ROUSSY and VP , Chief Medical Strategy Officer, at Cancer cam-pus Grand Paris.